Startseite Crystal structure of 1-(4-chloro-phenyl)-7-ethoxyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C18H12ClF2NO4
Artikel Open Access

Crystal structure of 1-(4-chloro-phenyl)-7-ethoxyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C18H12ClF2NO4

  • Liu-Hong Zou , Xu-Liang Nie ORCID logo , Lei Zhao , Guo-Ping Huang EMAIL logo und Jian-Ping Huang ORCID logo EMAIL logo
Veröffentlicht/Copyright: 24. April 2020

Abstract

C18H12ClF2NO4, monoclinic, P21/c (no. 14), a = 13.544(5) Å, b = 9.344(3) Å, c = 13.545(5) Å, β = 109.86°, V = 1612.4(10) Å3, Z = 4, Rgt(F) = 0.0393, wRref(F2) = 0.1058, T = 296(2) K.

CCDC no.: 1995270

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colorless block
Size:0.20 × 0.16 × 0.13 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.28 mm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
θmax, completeness:25.5°, >99%
N(hkl)measured, N(hkl)unique, Rint:12053, 2988, 0.033
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2251
N(param)refined:249
Programs:Bruker [1], SHELX [2], [3], Diamond [4]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.83318(14)0.0732(2)0.43218(14)0.0421(4)
C20.74913(15)−0.0206(2)0.39365(15)0.0481(5)
C30.72053(16)−0.1151(2)0.45689(17)0.0537(5)
C40.78124(18)−0.1169(2)0.56385(16)0.0561(5)
C50.86451(17)−0.0301(2)0.60473(16)0.0510(5)
H50.9037−0.03480.67590.061*
C60.89194(15)0.0670(2)0.54009(14)0.0421(4)
C70.97992(15)0.1630(2)0.58605(15)0.0451(5)
C81.00360(15)0.2577(2)0.51487(15)0.0437(4)
C90.94274(15)0.2596(2)0.41129(15)0.0459(5)
H90.95970.32460.36760.055*
C101.09032(16)0.3617(2)0.55004(17)0.0519(5)
C110.79339(15)0.2046(2)0.26158(14)0.0429(4)
C120.72062(16)0.3114(2)0.24645(16)0.0509(5)
H120.71630.36390.30320.061*
C130.65381(17)0.3405(2)0.14633(16)0.0547(5)
H130.60350.41210.13490.066*
C140.66227(16)0.2626(2)0.06386(15)0.0499(5)
C150.73762(17)0.1596(2)0.07809(16)0.0533(5)
H150.74400.11050.02090.064*
C160.80398(16)0.1295(2)0.17837(15)0.0503(5)
H160.85530.05930.18960.060*
C17a0.6243(3)−0.3329(4)0.4318(4)0.0703(16)
H17Aa0.5980−0.34630.48950.084*
H17Ba0.6936−0.37550.45200.084*
C180.5549(2)−0.4072(3)0.3393(3)0.0987(10)
H18A0.5857−0.40660.28510.148*
H18B0.4882−0.35960.31460.148*
H18C0.5453−0.50430.35740.148*
Cl10.57505(5)0.29522(8)−0.06195(4)0.0741(2)
F10.69051(10)−0.02017(14)0.29174(9)0.0693(4)
F20.75266(13)−0.20755(17)0.62604(11)0.0861(5)
N10.86015(12)0.17355(17)0.36877(12)0.0440(4)
O11.14296(13)0.36268(19)0.65210(12)0.0709(5)
H11.12130.29830.68050.106*
O21.11349(12)0.44157(17)0.49151(13)0.0653(4)
O31.03103(12)0.16004(17)0.68288(11)0.0612(4)
O40.63224(14)−0.1920(2)0.41624(15)0.0800(5)
C17Bd0.6119(7)−0.2834(10)0.3329(6)0.089(4)
H17Cb0.6781−0.31260.32640.107*
H17Db0.5729−0.23180.26950.107*
  1. aOccupancy: 0.635(8), bOccupancy: 0.365(8).

Source of material

To a stirred solution of 1-(4-chloro-phenyl)-6,7,8-trifluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester (38.2 g, 0.1 moL) in ethanol (200 mL) was added sodium hydroxide (4.0 g, 0.1 moL), and then the reaction mixture was refluxed for about 0.5 h. After the reaction was completed (monitored by TLC), the ethanol was evaporated under reduced pressure to give a crude product. The crude product was poured into water (40 mL) and extracted with EtOAc (50 mL × 3). The EtOAc solvent was evaporated to provide crystals of the title compound suitable for X-ray analysis in 84.5% yield. 1H NMR (400 MHz, CDCl3) δ 1.37–1.40 (t, J = 8.0 Hz, 3 H, CH3), 4.29–4.35 (q, J = 8.0, 16.0 Hz, 2 H, OCH2), 7.36–7.55 (m, 4 H, PhH), 8.05–8.07 (d, J = 8.0 Hz, 1 H, ArH), 8.58 (s, 1 H, NCH), 14.30 (br, 1 H, COOH) ppm. 13C NMR (100 MHz, CDCl3) δ = 176.03, 165.07, 149.57, 140.68, 135.70, 129.44, 126.39, 107.72, 107.53, 70.41, 14.76 ppm.

Experimental details

All H atoms were included in calculated positions and refined as riding atoms, with O—H = 0.82 Å with Uiso (H) = 1.2 Ueq (O), C—H = 0.93–0.98 Å) with Uiso(H) = 1.2–1.5 Ueq(C) [3].

Comment

Since the advent of naphthalic acid in the 1960s, quinolones are very important synthetic broad-spectrum antibiotics and the most important breakthroughs in antibiotic synthesis after sulfonamide [5], [6], [7], [8]. Owing the characteristics of wide antibacterial spectrum, strong antibacterial activity, convenient administration and no cross resistance with commonly used antibiotics, quinolones have been popularized rapidly in clinic, and become the key drug in the development, production and application in the world [9]. However, quinolones have been used or even abused for a long time, and bacteria have become seriously resistant to the quinolones through mutation and chromosome medium. Therefore, it is urgent to develop new quinolones effective against drug-resistant bacteria [10]. Recently, an expedient and high-yielding method for the synthesis of fluoroquinolones is explored in our group, and single crystals of several key intermediates are achieved. We have reported the synthesis and single crystals of a key intermediate 7-ethoxyl-6,8-difluoro-4-oxo-1-phenyl-1,4-dihydro-quinoline-3-carboxylic acid [11]. Herein, the synthesis and crystal structure of a key intermediate 1-(4-chloro-phenyl)-7-ethoxy-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid is disclosed.

In the molecule of the title compound bond lengths and angles are very similar to those given in the literature for directly related ones [12], [13], [14]. The molecule consists of two moieties: quinoline and substituted chloro-phenyl group. The chloro-phenyl group is connected to the nitrogen atom (N1) of the quinoline moiety. The dihedral angle of quinoline chloro-phenyl group and the carboxylate group C10-O1-O2 plane are 85.42(5)°, 3.35(10)° and 85.97(11)°, respectively. The torsion angles of C4-C3-O4-C17 and C3-O4-C17-C18 are −51.1(4)° and −143.3(3)°, respectively.

Acknowledgements

X-ray data were collected at Instrumental Analysis Center Nanchang Hangkong University, Nanchang, 330063, People’s Republic of China. This study was supported by grants from Natural Science Foundation of Science and Technology Department of Jiangxi Province (No. 20151BBF60081; 20171BBE50027; 20171BBG70029), Natural Science Foundation of Education Department of Jiangxi Province (No. GJJ170275), Natural Science Foundation of Nanchang City (No. 2014HZZC07, 2018CXTD014), and Natural Science Foundation of Jiangxi Agriculture University (No. 09004634; 09005194).

References

1. Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, WI, USA (2009).Suche in Google Scholar

2. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

3. Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Suche in Google Scholar PubMed PubMed Central

4. Brandenburg, K.: DIAMOND. Visual Crystal Structure Information System. Ver. 4.0. Crystal Impact, Bonn, Germany (2015).Suche in Google Scholar

5. Ma, Y.; Jin, S. H.: Development of fluoroquinolones. Foreign Med. Sci. 28 (2001) 240–242.Suche in Google Scholar

6. Xia, K. H.; Zhou, L.; Hao, L. F.: Progress in the research of the quinolone antibiotic. World Notes on Antibiot. 25 (2004) 138–141.Suche in Google Scholar

7. Schellhorn, C.: Classification of quinolones by vadriole. Infect. 26 (1998) 64–64.10.1007/BF02768762Suche in Google Scholar

8. Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; Haystead, T. A. J.: Discovery of novel targets of quinoline drugs in the human purine binding proteme. Mol. Pharmacol. 62 (2002) 1364–1364.10.1124/mol.62.6.1364Suche in Google Scholar PubMed

9. Chen, H. J.: Research progress of Quinolone compounds. Chin. J. Liaoning Chem. Ind. 48 (2019) 792–799.Suche in Google Scholar

10. Wang, A. P.; Feng, L. S.; Liu, M. L.; Guo, H. Y.: The latest research progress of fluoroquinolone. World Notes on Antibiot. 40 (2019) 171–179.Suche in Google Scholar

11. Huang, J. X.; Huang, C. X.; Huang, G. P.; Xiong, Y. Z.; Huang, J. P.: Crystal structure of 7-ethoxyl-6,8-difluoro-4-oxo-1-phenyl-1,4-dihydro-quinoline-3-carboxylic acid, C18H13F2N1O4. Kristallogr. NCS 235 (2020) DOI:https://doi.org/10.1515/ncrs-2019-0885.10.1515/ncrs-2019-0885Suche in Google Scholar

12. Weiss, R.; Bess, M.; Huber, S. M.; Heinemann, F. W.: Nucleophilic β-oniovinylation: concept, mechanism, scope and applications. J. Am. Chem. Soc. 130 (2008) 4610–4617.10.1021/ja071316aSuche in Google Scholar PubMed

13. Kuramoto, Y.; Ohshita, Y.; Yoshida, J.; Yazaki, A.; Shiro, M.; Koike, T.: A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-Amino-2,4-difluorophenyl) Group. J. Med. Chem. 46 (2003) 1905–1917.10.1021/jm0205090Suche in Google Scholar PubMed

14. Yang, X.; Qian, Xu.; Cao, R.; Xu, H.; Wang, Qi.: The crystal structure of 7-bromo-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid an intermediate of the ozenoxacin synthesis, C14H12BrNO3. Z. Kristallogr. NCS 233 (2018), 667–668.10.1515/ncrs-2017-0430Suche in Google Scholar

Received: 2020-03-05
Accepted: 2020-04-07
Published Online: 2020-04-24
Published in Print: 2020-06-25

©2020 Liu-Hong Zou et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Artikel in diesem Heft

  1. Frontmatter
  2. Crystal structure of bis [1-(phenylsulfonyl)-2-(1-(pyrazin-2-yl)ethylidene)hydrazin-1-ido-κ3N,N′,O]cobalt(II), C24H22N8O4S2Co
  3. The crystal structure of 1,3-bis(4-(methoxycarbonyl)benzyl)-2-methyl-1H-benzo[d]imidazol-3-ium bromide, C26H25BrN2O4
  4. Crystal structure of {tris((1H-benzo[d]imidazol-2-yl)methyl)amine-κ4N,N′,N′′,N′′′}-(nitrito-κ2O,O′)nickel(II) perchlorate – ethanol (1/1), C26H27ClN8NiO7
  5. Crystal structure of catena-poly[aqua[(μ2-4,5-dicarboxylato-2-(2-carboxylatophenyl)imidazol-1-ido-κ4N,O,O′:N′)](μ2-4,4′-bipyridine-κ2N:N′)dicopper(II)], C22H14Cu2N4O7
  6. Crystal structure of chlorido-tris(4-methylbenzyl-κC)-(triphenylarsine oxide-κO)tin(IV), C42H42AsClOSn
  7. The crystal structure of 4,4′-bipyridinium bis(3-carboxy-2-nitrobenzoate) tetrahydrate, C13H13N2O8
  8. Crystal structure of 1-(3-chlorophenyl)-4-(4-(((2,3-dihydro-1H-inden-5-yl)oxy)methyl)phenethyl)piperazine, C28H31ClN2O
  9. Crystal structure of catena-poly[diaqua-bis(μ2-5,5′-(1H-imidazole-4,5-diyl)bis(tetrazol-2-ido)-κ4N,N′:N′′,N′′′)magnesium], C10H8N20O2Mg
  10. The crystal structure of (E)-2-((2-hydroxy-4-ethoxybenzylidene)amino)-2-methylpropane-1,3-diol monohydrate, C13H21NO5
  11. Crystal structure of catena-poly[diaqua-(μ2-bipyridine-κ2N:N′)-bis(3,5-dichloroisonicotinato-κO)cadmium(II)] dihydrate, C22H20CdCl4N4O8
  12. The crystal structure of 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid, C13H15ClO2
  13. Redetermination of the crystal structure of yttrium(III) trinitrate(V) pentahydrate, Y(NO3)3 ⋅ 5 H2O, H10N3O14Y
  14. Crystal structure of catena-poly[di-μ2-chlorido-1,10-phenanthroline-κ2N,N′-cadmium(II)], C12H8Cl2CdN2
  15. Crystal structure of 4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid, C13H9F3N2O3
  16. Crystal structure of 3-acetyl-4-hydroxybenzoic acid, C18H16O8
  17. Crystal structure of bis(N,2-bis(4-ethoxybenzylidene)hydrazine-1-carbohydrazonothioato-κ2N,S)nickel(II) — N,N-dimethylformamide (1/2), C44H56N10S2O6Ni
  18. The crystal structure of 5-chloro-4,6-dimethoxypyrimidin-2-amine, C6H8ClN3O2
  19. Crystal structure of poly[aqua-(μ4-benzene-1,2,4,5-tetracarboxylato-κ4O,O′,O′′,O′′′)bis(μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N)dinickel(II)], NiC17H14N5O5
  20. Crystal structure of poly[aqua(5-dimethylamino)naphthalene-1-sulfonato-κ2N:O)(μ2-4,4′-bipyridyl -κ2N:N′)silver(I)], C44H44Ag2N6O8S2
  21. Crystal structure of 1-[3-(trifluoromethyl)cinnamoyl]-3-(pyridin-2-yl-κN)pyrazole-κ2N-bis(2-phenylpyridinato-k2C,N)iridium(III) hexafluorophosphate complex, [C40H28F3IrN5O]PF6
  22. Crystal structure of catena-poly[aqua(μ6-piperazine-1,4-bisethanesulfonato-κ6N:N′:O:O′:O′′:O′′′)(μ2-pyrazinyl-κ2N:N′)disilver(I)sesquihydrate], C12H30Ag2N4O11S2
  23. Crystal structure of (E)-1-(2-nitrophenyl)-N-(o-tolyl)methanimine, C14H12N2O2
  24. Crystal structure of 4′-amino-3′,5′-diisopropyl-(1,1′-biphenyl)-4-carbonitrile, C19H22N2
  25. The crystal structure of poly[bis(N,N-dimethylformamide-κ1O)-tetrakis(μ2-cyanido-κ2C:N)dinickel(II)], C10H14N6O2Ni2
  26. Crystal structure of rac-trans-N,N′-bis(3-bromo-5-chlorosalicylidene)-1,2-cyclohexanediamine, C20H18Br2Cl2N2O2
  27. Crystal structure of rac-trans-N,N′-bis(3,5-dibromosalicylidene)-1,2-cyclohexanediamine, C20H18Br4N2O2
  28. The crystal structure of (dichromato-κ2O,O′)bis(1,10-phenanthroline-κ2N,N′)nickel(II), C12H16N4O7Cr2Ni
  29. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridozincate(II) monohydrate, C10H18Cl4ZnN2O
  30. Crystal structure of bis(μ2-azido-k2N,N)-bis(2-amino-1-(N-(3-bromosalicylaldiminato))ethane)-dicopper(II), C20H18Br4N2O2
  31. Crystal structure of (η6-1-methyl-4-isopropylbenzene)-[5-bromo-2-(2-pyridyl)phenyl-κ2C,N]-chloro-ruthenium(II), C21H21BrClNRu
  32. Crystal structure of N-(methyl(oxo)(1-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-λ6-sulfanylidene)cyanamide, C10H10F3N3OS
  33. Crystal structure of 6,6′-((cyclohexane-1,2-diylbis(azanylylidene))bis(methanylylidene))bis(2-bromo-4-chlorophenolato-κ4N,N′,O,O′)nickel(II), C20H16Br2Cl2NiN2O2
  34. Redetermination of the crystal structure of catena-poly[aqua-(1,10-phenanthroline-κ2N,N′)-(μ2-tetraoxidomolybdato(VI)-κ2O:O′)manganese(II) monohydrate, C12H12N2O6MoMn
  35. The crystal structure tetrakis(μ2-o-chlorobenzoato-κ2O:O′)-bis(methanol-κ1O)dirhodium(II), C30H24Cl4O10Rh2
  36. Crystal structure of bis(2,3-diphenyltetrazolidine-5-thione-κ1S)-(nitrato-κ1O)-(nitrato-κ2O,O′)lead(II), C26H20N10O6S2Pb
  37. Crystal structure of bis(3-bromo-N-(1-(3-methylpyrazin-2-yl)ethylidene)benzohydrazonato-κ3O,N,N′)cadmium(II) hemihydrate, C28H25N8O2.5Br2Cd
  38. Crystal structure of catena-poly[tetrakis(μ2-trifluoroacetato-κ2O:O′)(μ2-2,5-dimethylpyrazine-κ2N,N′)dicopper(II)], C7H4CuF6NO4
  39. The crystal structure of catena-poly[bis[3-azoniapentane-1,5-diammonium][bis(μ4-oxo)-tetrakis(μ3-oxo)-heptakis(μ2-oxo)-tetradecaoxo-octa-molybdenum] dihydrate], (C8H36N6O29Mo8)n
  40. Crystal structure of tetraaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-κO)-nickel(II)—diaqua-bis(2-((3,5,6-trichloropyridin-2-yl)oxy)acetato-nickel(II), C28H24Cl12N4Ni2O18
  41. The crystal structure of bis(2-hydroxypyrimidinium) pentachloridobismuthate(III), (C4N2H5O)2BiCl5
  42. The crystal structure of catena-poly[(μ2-4,4′-dipyridine-κ2N,N′)-bis(3,5,6-trichloropyridine-2-oxyacetato-κO)-bis(ethanol-κO)nickel(II)], C28H26Cl6N4NiO8
  43. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3,5-bis(4-fluorobenzylidene)piperidin-4-one-dichloromethane (1/1), C26H20Cl3F2NO3S
  44. The crystal structure of 5-bromopicolinic acid monohydrate, C6H6BrNO3
  45. The crystal structure of 2-(3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-8H-indeno[1,2-d]thiazole, C25H17BrFN3S
  46. The crystal structure of catena-poly[(μ2-2-((3-bromo-2-oxidobenzylidene)amino)acetato-κ4O,N,O′:O′′)-(dimethylformamide-κ1O)]zinc(II), C12H13N2O4BrZn
  47. Crystal structure of aqua-azido-κ1N-(6,6′-((propane-1,3-diylbis(azanylylidene))bis(methanylylidene))bis(3-bromophenolato)-κ4N,N′,O,O′iron(III), C17H16Br2FeN5O3
  48. The crystal structure of tris(1-ethylimidazole-κ1N)-(sulfato-κ2O,O′)vanadium(IV), C15H24N6O5SV
  49. Crystal structure of (E)-3-methoxy-N′-(1-(pyridin-2-yl)ethylidene)benzohydrazide, C15H15N3O2
  50. Crystal structure of dichloro-bis-(1-butyl-1H-benzo[d]imidazole)-nickel(II), C22H28Cl2N4Ni
  51. The crystal structure of 2-(2,3-dimethoxyphenyl)-3-hydroxy-4H-chromen-4-one, C17H14O5
  52. The crystal structure of 5-(2-(4-fluorophenyl)hydrazono)-4-methyl-2-((3-(5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene) hydrazono)-2,5-dihydrothiazole dimethylformamide monosolvate, C30H25FN10S⋅C3H7NO
  53. The crystal structure of 1,8-bis(pyridin-4-ylethynyl)anthracene-1,2,4,5-tetrafluoro-3,6-diiodobenzene (2/1), C62H32F4I2N4
  54. The crystal structure of 3,6-di-tert-butyl-1,8-diiodo-9-methyl-9H-carbazole, C21H25I2N
  55. The crystal structure of 8-((4-chlorophenylamino)methylene)-6,10-dioxaspiro[4.5]decane-7,9-dione, C15H14ClNO4
  56. The crystal structure of catena-poly[oktaaqua-bis(μ2-4,4′-ethene-1,2-diyldipyridine-κ2N:N′)-(μ2-3,3′-(1-oxidodiazene-1,2-diyl)diphthalato-κ2O:O′)dicobalt(II)] dihydrate, C28H36N4O19Co2
  57. Crystal structure of (E)-1-(2-cyano-3-oxo-1-phenylprop-1-en-1-yl)-3,7-diphenylindolizine-6-carbonitrile, C31H19N3O
  58. Crystal structure of 1,1′-bis(diphenylphosphino)ferrocene-(1,1′-bis(diphenylphosphino)ferrocene-κ2P,P′)-(O-isobutyl sulfurodithioito-κ2S,S′)copper(I), C39H37CuFeOP2S2
  59. Crystal structure of poly[(5-bimethylamino-1-naphthalenesulfonato-κO)-(μ3-hexamethylenetetramino-κ3N:N′:N′′)silver(I)] dihydrate, C36H52Ag2N10O8S2
  60. Crystal structure of poly[μ2-diaqua-(μ2-2-amino-4,5-dicyano-κ2N:N′-imidazol-1-ide)sodium(I)], C5H6N5O2Na
  61. Crystal structure of (1,3-propanediamine-κ2N,N′)(N-(3-aminopropyl)-α-methyl aspartato-κ4N,N′,O,O′)cobalt(III) chloride, C11H24ClCoN4O4
  62. Crystal structure and anti-inflammatory activity of (3E,5E)-3,5-bis(4-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)piperidin-4-one-dichloromethane (1/1), C26H20Cl2F3NO3S
  63. Crystal structure of (S)-(+)-1-cyclohexylethylaminium chloride, C8H18NCl
  64. The crystal structure of tris(nitrato-κ2O,O′)-bis(4,4,5,5-tetramethyl-2-(o-pyridyl)imidazoline-1-oxyl 3-oxide-κ2N,O)yttrium(III), C24H32N9O13Y
  65. Hydrogen bonding versus packing effects in the crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetraiodidozincate(II), C10H16I4ZnN2
  66. Dimerization of 2-[(2-((2-aminophenyl)thio)phenyl)amino]-cyclohepta-2,4,6-trien-1-one through hydrogen bonding, C19H16N2OS
  67. Crystal structure of 1-(4-chloro-phenyl)-7-ethoxyl-6,8-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, C18H12ClF2NO4
  68. Crystal structure of 7-ethoxy-6,8-difluoro-4-oxo-1-pyridin-2-ylmethyl-1,4-dihydro-quinoline-3-carboxylic acid, C18H14F2N2O4
  69. Crystal structure of octahydro-7aR,8′R-dimethylspiro[isobenzofuran-4(1H), 4′ (3′H)-[1H-7,9a]methanocyclohepta[c]pyran]-1′,3, 9′ (3aH,4′aH)-trione, C20H26O5
  70. Crystal structure of bis(5-ethoxy-2-(((1-hydroxy-2-methyl-3-oxidopropan-2-yl)imino)methyl)phenolato-κ3N,O,O’)manganese(IV) – methanol (1/1), C27H38MnN2O9
  71. Crystal structure of 8a,8a′′-oxybis(8aH-8,9-dioxa-3a1λ4-aza-8aλ4-borabenzo[fg]tetracene), C34H22B2N2O5
  72. Crystal structure of bromido-triphenyl-(triphenylarsine oxide-κO)tin(IV), C36H30AsBrOSn
  73. Crystal structure of catena-poly[chlorido-(μ2-formato-κ2O:O′)-(1,10-phenathroline-κ2N,N′)copper(II)], C26H18Cl2Cu2N4O4
  74. The crystal structure of poly[(μ10-5-carboxyisophthalato-κ10O)disodium], C9H4Na2O6
  75. The crystal structure of 3,5-difluoroisonicotinic acid, C6H3F2NO2
  76. The crystal structure of ethyl-1-(N-(adamantan-1-yl)-carbamothioyl)piperidine-4-carboxylate, C19H30N2O2S
  77. Crystal structure of 5-methyl-3-phenyl-1-tosyl-1,2,3,4-tetrahydropyridine, C19H21NO2S
  78. Crystal structure of bis((3-chlorosalicylidene)-ethylenediaminato-κ4N,N′,O,O′)nickel (II), C16H12Cl2NiN2O2
  79. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-4-hydroxybenzohydrazide — dihydrofuran-2(3H)-one (1/1), C18H17ClN2O5
  80. Crystal structure of bis((3-bromosalicylidene)-ethylenediaminato-κ4N,N′,O,O′) nickel (II), C16H12Br2NiN2O2
  81. Crystal structure of trimethylsulfoxonium tetrachloridocobaltate(II) [(CH3)3SO]2CoCl4
Heruntergeladen am 29.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0125/html?lang=de
Button zum nach oben scrollen